1. Home
  2. EARN vs GBIO Comparison

EARN vs GBIO Comparison

Compare EARN & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • GBIO
  • Stock Information
  • Founded
  • EARN 2012
  • GBIO 2016
  • Country
  • EARN United States
  • GBIO United States
  • Employees
  • EARN N/A
  • GBIO N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • GBIO Health Care
  • Exchange
  • EARN Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • EARN 187.6M
  • GBIO 64.8M
  • IPO Year
  • EARN 2013
  • GBIO 2020
  • Fundamental
  • Price
  • EARN $6.48
  • GBIO $0.88
  • Analyst Decision
  • EARN Hold
  • GBIO Strong Buy
  • Analyst Count
  • EARN 1
  • GBIO 2
  • Target Price
  • EARN N/A
  • GBIO $6.50
  • AVG Volume (30 Days)
  • EARN 524.2K
  • GBIO 581.0K
  • Earning Date
  • EARN 03-05-2025
  • GBIO 03-05-2025
  • Dividend Yield
  • EARN 14.79%
  • GBIO N/A
  • EPS Growth
  • EARN 277.67
  • GBIO N/A
  • EPS
  • EARN 1.02
  • GBIO N/A
  • Revenue
  • EARN N/A
  • GBIO $18,582,000.00
  • Revenue This Year
  • EARN N/A
  • GBIO $212.74
  • Revenue Next Year
  • EARN $89.08
  • GBIO N/A
  • P/E Ratio
  • EARN $6.33
  • GBIO N/A
  • Revenue Growth
  • EARN N/A
  • GBIO 514.08
  • 52 Week Low
  • EARN $5.54
  • GBIO $0.75
  • 52 Week High
  • EARN $7.26
  • GBIO $4.65
  • Technical
  • Relative Strength Index (RSI)
  • EARN 42.60
  • GBIO 28.66
  • Support Level
  • EARN $6.30
  • GBIO $0.85
  • Resistance Level
  • EARN $6.68
  • GBIO $1.01
  • Average True Range (ATR)
  • EARN 0.13
  • GBIO 0.12
  • MACD
  • EARN -0.02
  • GBIO 0.00
  • Stochastic Oscillator
  • EARN 32.14
  • GBIO 7.50

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: